Publications
Detailed Information
PAPILLARY MICROCARCINOMA IN COMPARISON WITH LARGER PAPILLARY THYROID CARCINOMA IN BRAF(V600E) MUTATION, CLINICOPATHOLOGICAL FEATURES, AND IMMUNOHISTOCHEMICAL FINDINGS
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Young Joo | - |
dc.contributor.author | Kim, Young A. | - |
dc.contributor.author | Lee, You Jin | - |
dc.contributor.author | Kim, Soon Hui | - |
dc.contributor.author | Kim, Kyung Won | - |
dc.contributor.author | Youn, Yeo Kyu | - |
dc.contributor.author | Park, Do Joon | - |
dc.contributor.author | Cho, Bo Youn | - |
dc.contributor.author | Kim, Kwang Hyun | - |
dc.contributor.author | Chung, June Key | - |
dc.contributor.author | Park, So Yeon | - |
dc.date.accessioned | 2012-05-29T07:00:08Z | - |
dc.date.available | 2012-05-29T07:00:08Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.citation | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK; Vol.32 1; 38-45 | ko_KR |
dc.identifier.issn | 1043-3074 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76561 | - |
dc.description.abstract | Background. Papillary thyroid microcarcinoma (PMC; <= 51 cm) is thought to take a benign course during the lifetime. However, recent studies showed high recurrence rates for PMC. Methods. We analyzed the clinicopathological features, long-term prognosis, and some molecular characteristics including BRAF(V600E) mutation by retrospectively reviewing the records of 1150 patients with papillary thyroid carcinoma (PTC), 278 with PMC, and 868 with PTC > 1 cm. Results. The prevalence of extrathyroidal invasion (52.2%) and initial nodal metastasis (34.9%) in patients with PMC was surprisingly high and almost as high as that for patients with PTC (72.4% and 51.8%, respectively). The rate of recurrent or persistent disease did not differ between patients with PMC and PTC (recurrent or persistent disease, 6.1% vs 14.1%: 53.4- vs 84.2-month follow-up; n = 98 vs 647; corrected P = .112). The frequency of BRAF(V600E) mutation was similar in patients with PMC and PTC (65.6% vs 67.2%). Immunohistochemical staining showed no different expression pattern according to the tumor size. Conclusion. These results suggest that PMC is not an occult cancer and it can act like larger PTC. Therefore, PMC should not be underestimated in practice. (C) 2009 Wiley Periodicals, Inc. Head Neck 32: 38-45, 2010 | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | JOHN WILEY & SONS INC | ko_KR |
dc.subject | papillary thyroid carcinoma | ko_KR |
dc.subject | papillary thyroid microcarcinoma | ko_KR |
dc.subject | immunohistochemistry | ko_KR |
dc.subject | clinicopathological features | ko_KR |
dc.subject | BRAF mutation | ko_KR |
dc.title | PAPILLARY MICROCARCINOMA IN COMPARISON WITH LARGER PAPILLARY THYROID CARCINOMA IN BRAF(V600E) MUTATION, CLINICOPATHOLOGICAL FEATURES, AND IMMUNOHISTOCHEMICAL FINDINGS | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박영주 | - |
dc.contributor.AlternativeAuthor | 김영아 | - |
dc.contributor.AlternativeAuthor | 이유진 | - |
dc.contributor.AlternativeAuthor | 김순희 | - |
dc.contributor.AlternativeAuthor | 박소연 | - |
dc.contributor.AlternativeAuthor | 김경원 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 윤여규 | - |
dc.contributor.AlternativeAuthor | 김광현 | - |
dc.contributor.AlternativeAuthor | 박도준 | - |
dc.contributor.AlternativeAuthor | 조보연 | - |
dc.identifier.doi | 10.1002/hed.21142 | - |
dc.citation.journaltitle | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | - |
dc.description.citedreference | Lupi C, 2007, J CLIN ENDOCR METAB, V92, P4085, DOI 10.1210/jc.2007-1179 | - |
dc.description.citedreference | Rodolico V, 2007, CANCER, V110, P1218, DOI 10.1002/cncr22912 | - |
dc.description.citedreference | Lee JH, 2007, CANCER, V110, P38, DOI 10.1002/cncr.22754 | - |
dc.description.citedreference | Hay ID, 2006, J SURG ONCOL, V94, P692, DOI 10.1002/jso.20696 | - |
dc.description.citedreference | Roti E, 2006, J CLIN ENDOCR METAB, V91, P2171, DOI 10.1210/jc.2005-2372 | - |
dc.description.citedreference | Lo CY, 2006, WORLD J SURG, V30, P759, DOI 10.1007/s00268-005-0363-8 | - |
dc.description.citedreference | Chen YK, 2005, ANTICANCER RES, V25, P1421 | - |
dc.description.citedreference | Kovacs GL, 2005, THYROID, V15, P152 | - |
dc.description.citedreference | Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235 | - |
dc.description.citedreference | Ito Y, 2005, ANTICANCER RES, V25, P179 | - |
dc.description.citedreference | Sedliarou I, 2004, INT J ONCOL, V25, P1729 | - |
dc.description.citedreference | Ito Y, 2004, WORLD J SURG, V28, P1115, DOI 10.1007/s00268-004-7644-5 | - |
dc.description.citedreference | Bojunga J, 2004, CLIN ENDOCRINOL, V61, P523, DOI 10.1111/j.1365-2265.2004.02131.x | - |
dc.description.citedreference | Kim KH, 2004, YONSEI MED J, V45, P818 | - |
dc.description.citedreference | Pellegriti G, 2004, J CLIN ENDOCR METAB, V89, P3713, DOI 10.1210/jc.2003-031982 | - |
dc.description.citedreference | Pearce EN, 2004, J CLIN ENDOCR METAB, V89, P3710, DOI 10.1210/jc.2004-1189 | - |
dc.description.citedreference | Pelizzo MR, 2004, NUCL MED COMMUN, V25, P547, DOI 10.1097/01.mnm.0000126625.17166.36 | - |
dc.description.citedreference | Silver RJ, 2004, SURG CLIN N AM, V84, P907, DOI 10.1016/j.suc.2004.02.002 | - |
dc.description.citedreference | Nam-Goong IS, 2004, CLIN ENDOCRINOL, V60, P21, DOI 10.1046/j.1365-2265.2003.01912.x | - |
dc.description.citedreference | Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838 | - |
dc.description.citedreference | Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305 | - |
dc.description.citedreference | Chow SM, 2003, CLIN ONCOL-UK, V15, P329, DOI 10.1016/S0936-6555(03)00066-9 | - |
dc.description.citedreference | Xu XL, 2003, CANCER RES, V63, P4561 | - |
dc.description.citedreference | Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706 | - |
dc.description.citedreference | Chow SM, 2003, CANCER, V98, P31, DOI 10.1002/cncr.11442 | - |
dc.description.citedreference | Kimura ET, 2003, CANCER RES, V63, P1454 | - |
dc.description.citedreference | Ito Y, 2003, THYROID, V13, P381 | - |
dc.description.citedreference | COHEN Y, 2003, J NATL CANCER I, V95, P625 | - |
dc.description.citedreference | Appetecchia M, 2002, J EXP CLIN CANC RES, V21, P159 | - |
dc.description.citedreference | Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941 | - |
dc.description.citedreference | Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814 | - |
dc.description.citedreference | Timler D, 2001, FOLIA HISTOCHEM CYTO, V39, P201 | - |
dc.description.citedreference | Wang S, 2000, MODERN PATHOL, V13, P882 | - |
dc.description.citedreference | Nasir A, 2000, IN VIVO, V14, P367 | - |
dc.description.citedreference | Liberman E, 2000, APPL IMMUNOHISTO M M, V8, P42 | - |
dc.description.citedreference | Baudin E, 1998, CANCER, V83, P553 | - |
dc.description.citedreference | Resnick MB, 1998, MODERN PATHOL, V11, P735 | - |
dc.description.citedreference | Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737 | - |
dc.description.citedreference | HAY ID, 1992, SURGERY, V112, P1139 | - |
dc.description.citedreference | HAY ID, 1992, SURGERY, V112, P1146 | - |
dc.description.citedreference | YAMAMOTO Y, 1990, CANCER, V65, P1173 | - |
dc.description.citedreference | SCHELFHOUT LJDM, 1989, AM J CLIN PATHOL, V92, P654 | - |
dc.description.citedreference | HARACH HR, 1985, CANCER, V56, P531 | - |
dc.description.citedreference | BONDESON L, 1981, CANCER, V47, P319 | - |
dc.description.tc | 9 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.